Collegium Pharmaceutical

COLL · NASDAQ

$23.23+$0.22 (+0.96%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $23.01

Latest news

NewsOct 5, 6:29 AM ET
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseAug 13, 7:30 AM ETGlobe Newswire
Collegium Announces $50 Million Accelerated Share Repurchase Program
Press releaseAug 6, 7:30 AM ETGlobe Newswire
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
Press releaseJul 23, 8:00 AM ETGlobe Newswire
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
Press releaseMay 12, 7:31 AM ETGlobe Newswire
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
NewsMay 7, 7:30 AM ET
Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Estimate
Press releaseMay 7, 7:30 AM ETGlobe Newswire
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Press releaseApr 23, 8:00 AM ETGlobe Newswire
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
NewsMar 19, 8:02 AM ET
Collegium To Acquire AZSTARYS For $650M In Cash With Potential For Additional Milestone Payments Up To $135M Depending On Future Commercial And Regulatory Milestones
Press releaseMar 19, 8:00 AM ETGlobe Newswire
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
Press releaseMar 5, 8:00 AM ETGlobe Newswire
Collegium to Present New Real-World Data at PainConnect 2026
Press releaseMar 3, 8:00 AM ETGlobe Newswire
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
NewsFeb 26, 3:00 PM ET
Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings)
NewsFeb 26, 7:34 AM ET
Insights into Collegium Pharmaceutical Q4 Earnings
NewsFeb 26, 7:33 AM ET
Collegium Pharmaceutical Q4 Adj. EPS $2.04 Misses $2.33 Estimate, Sales $205.449M Miss $206.362M Estimate
Press releaseFeb 26, 7:30 AM ETGlobe Newswire
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
NewsJan 9, 7:01 AM ET
What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
Press releaseJun 18, 8:45 AM ETGlobe Newswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsApr 9, 5:01 PM ET
What Analysts Are Saying About Collegium Pharmaceutical Stock
NewsMar 24, 9:00 AM ET
Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical
NewsSep 5, 8:00 AM ET
The Analyst Landscape: 4 Takes On Collegium Pharmaceutical
NewsAug 9, 11:00 AM ET
The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript

Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Estimate

Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium to Report First Quarter 2026 Financial Results on May 7, 2026

Collegium To Acquire AZSTARYS For $650M In Cash With Potential For Additional Milestone Payments Up To $135M Depending On Future Commercial And Regulatory Milestones

Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory

Collegium to Present New Real-World Data at PainConnect 2026

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community

Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings)

Insights into Collegium Pharmaceutical Q4 Earnings

Collegium Pharmaceutical Q4 Adj. EPS $2.04 Misses $2.33 Estimate, Sales $205.449M Miss $206.362M Estimate

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results

What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical

Earnings Scheduled For November 6, 2025

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Earnings Scheduled For May 8, 2025

What Analysts Are Saying About Collegium Pharmaceutical Stock

Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical

The Analyst Landscape: 4 Takes On Collegium Pharmaceutical

The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts